The case for maternal vaccination against pertussis. 2007

Frits R Mooi, and Sabine C de Greeff
Laboratory for Infectious Diseases and Perinatal Screening, National Institute of Public Health and the Environment, Bilthoven, Netherlands. fr.mooi@rivm.nl

Despite high vaccine coverage, the incidence of pertussis is increasing in a number of countries. Particularly alarming is the increase of pertussis in infants too young to be (fully) vaccinated, because the highest morbidity and mortality is observed in this category. Maternal vaccination offers the possibility to protect infants from birth until immunity is induced by active vaccination, and has been shown to be effective and safe for tetanus over long periods of time. Maternal vaccination studies with whole-cell pertussis vaccines have not shown serious adverse effects in mother and child. In one study, protection of newborn babies was found. Additional support for the efficacy of maternal vaccination comes from studies showing that transfer of antibodies confers protection against pertussis. Maternal vaccination might be an effective way to decrease morbidity and mortality caused by pertussis in newborn babies.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D009017 Morbidity The proportion of patients with a particular disease during a given year per given unit of population. Morbidities
D010567 Pertussis Vaccine A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed) Vaccine, Pertussis
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014917 Whooping Cough A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath. Pertussis,Bordetella pertussis Infection, Respiratory,Cough, Whooping,Pertusses

Related Publications

Frits R Mooi, and Sabine C de Greeff
April 2008, The Lancet. Infectious diseases,
Frits R Mooi, and Sabine C de Greeff
February 2018, Obstetrics and gynecology,
Frits R Mooi, and Sabine C de Greeff
March 1972, Memoires de l'Academie royale de medecine de Belgique,
Frits R Mooi, and Sabine C de Greeff
February 1953, Postgraduate medical journal,
Frits R Mooi, and Sabine C de Greeff
June 1977, Lakartidningen,
Frits R Mooi, and Sabine C de Greeff
September 2017, Archives of disease in childhood. Fetal and neonatal edition,
Frits R Mooi, and Sabine C de Greeff
September 2020, Pediatrics,
Frits R Mooi, and Sabine C de Greeff
April 2019, American family physician,
Frits R Mooi, and Sabine C de Greeff
October 2010, Journal for specialists in pediatric nursing : JSPN,
Frits R Mooi, and Sabine C de Greeff
January 1949, Paris medical,
Copied contents to your clipboard!